Cetuximab improves AZD6244 antitumor activity in colorectal cancer HT29 cells in vitro and in nude mice by attenuating HER3/Akt pathway activation

The present study investigated the molecular mechanism by which the epidermal growth factor receptor (EGFR) inhibitor cetuximab enhances the antitumor activity of the mitogen-activated protein kinase kinase (MEK) inhibitor AZD6244 in colorectal cancer HT29 cells. HT29 cells were treated with AZD6244...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qin, Xiao, He, Jin, Feng, Li, Mengxia, Luo, Jia, Wang, Ge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006326/
https://www.ncbi.nlm.nih.gov/pubmed/29928418
http://dx.doi.org/10.3892/ol.2018.8674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006326/
https://www.ncbi.nlm.nih.gov/pubmed/29928418
http://dx.doi.org/10.3892/ol.2018.8674

Ejemplares similares